Exclusive License to RAD51C Gene Could Lead to New Myriad Test for Breast, Ovarian Cancer Risk | GenomeWeb

Originally published Jan. 20.

By Turna Ray

Having garnered an exclusive license to patents covering the use of the RAD51C gene to assess women's risk for hereditary breast and ovarian cancer, Myriad Genetics may be working on developing a new diagnostic panel that would strengthen the company's position in a testing market it already dominates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."